文献速递神经肿瘤小儿神经外科与脑积水

使用对流增强递送放射性免疫诊疗剂124I-Omburtamab治疗弥漫性内生性桥脑胶质瘤的1期剂量递增试验

Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma.
PubMed 文献 · Neuro Oncol · 2025-01-01

这项1期开放标签3+3剂量递增试验在50例儿童弥漫性内生性桥脑胶质瘤患者中,于标准外照射放疗后经MR引导立体定向对流增强递送靶向B7-H3的124I-Omburtamab。最大耐受活度为6 mCi(222 MBq),11例出现治疗相关3级中枢神经系统毒性,无4级或5级中枢神经系统毒性,中位生存期15.29个月。

要点

  • 最大耐受活度按研究方案确定为6 mCi(222 MBq)。
  • 11例出现治疗相关3级中枢神经系统毒性,无4级或5级中枢神经系统毒性。
  • 诊断起中位生存期15.29个月(95%CI:12.20-16.83个月)。

核心结论

  • 经对流增强递送124I-Omburtamab是弥漫性内生性桥脑胶质瘤的安全治疗选择,并确定了最大耐受活度水平。
  • 本研究是124I放射性药物首次在人体中同时作为显像剂和治疗剂的双重诊疗应用。

研究设计与样本

  • 1期、开放标签、3+3剂量递增试验,入组儿童弥漫性内生性桥脑胶质瘤患者。
  • 在标准外照射放疗完成后,经MR引导立体定向对流增强递送靶向B7-H3的124I-Omburtamab至脑干。
  • 50例儿童接受治疗并可评估。
  • 124I-Omburtamab活度从0.25递增至10.0 mCi(9.25-370 MBq),体积从0.25 mL递增至10.0 mL,给药后系列PET/MRI。
  • 安全性为主要结局,按美国国家癌症研究所不良事件通用术语标准评估给药后30天;次要结局包括总生存和病灶-全身吸收剂量比。

主要发现

  • 按研究方案确定的最大耐受活度为6 mCi(222 MBq)。
  • 在所有活度水平下,病灶总吸收剂量每单位注射活度的总体均值(±SD)为35.2 ± 18 cGy/MBq,病灶-全身吸收剂量比平均为816。
  • 11例患者出现治疗相关3级中枢神经系统毒性,无4级或5级中枢神经系统毒性。
  • 发生5例剂量限制性毒性事件。
  • 诊断起中位生存期为15.29个月(95%CI:12.20-16.83个月)。

关键数值与推荐

  • 最大耐受活度按研究方案为6 mCi(222 MBq)。
  • 治疗相关3级中枢神经系统毒性11例,无4级或5级中枢神经系统毒性。
  • 剂量限制性毒性事件5例。
  • 诊断起中位生存期15.29个月(95%CI:12.20-16.83个月)。
  • 1年、2年、3年生存率估计分别为65.4%(CI 53.3-80.1%)、18.4%(CI:10.2-33.2%)、11.7%(CI:5.3-25.7%)。

临床怎么用

  • 作者认为经对流增强递送124I-Omburtamab是弥漫性内生性桥脑胶质瘤的安全治疗选择,并确定了最大耐受活度水平。
  • 作者指出本研究是124I放射性药物首次在人体中同时作为显像剂和治疗剂的双重诊疗应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Median survival for patients with Diffuse Intrinsic Pontine Glioma (DIPG) is 8-12 months. METHODS: A phase 1, open label, 3 + 3 dose-escalation trial delivered radiolabeled 124I-Omburtamab, targeting B7-H3, using MR-guided stereotactic convection-enhanced delivery (CED) into the brainstem of pediatric DIPG patients. CED was performed after completion of standard-of-care external-beam radiation therapy (EBRT). Fifty children were treated and evaluable. 124I-Omburtamab activity was escalated from 0.25 to 10.0 mCi (9.25-370 MBq) and volume escalated from 0.25 mL to 10.0 mL with serial PET/MRI post administration. Safety was the primary outcome. National Cancer Institute Common Terminology Criteria for Adverse Events were assessed for 30 days following CED of 124I-Omburtamab. Secondary outcomes included overall survival and lesion-to-whole-body absorbed dose ratio. RESULTS: The maximum tolerated activity per study protocol was determined to be 6mCi (222 MBq). The overall mean (±SD) total absorbed dose in the lesion per unit injected activity was 35.2 ± 18 cGy/MBq with a high lesion-to-whole-body absorbed dose ratio averaging 816, across all activity levels. Eleven patients had treatment-related grade 3 CNS toxicities with no grade-4 or -5 CNS toxicities. Five dose-limiting toxicity events occurred. Median survival was 15.29 months from diagnosis (95% CI: 12.20-16.83 months). Survival rate estimates at 1, 2, and 3 years were 65.4% (CI 53.3-80.1%), 18.4% (CI: 10.2-33.2%), and 11.7% (CI: 5.3-25.7%), respectively. CONCLUSIONS: Administration of 124I-Omburtamab via CED is a safe treatment option for DIPG, with a maximum tolerated activity level identified. This study represents the first-in-human theranostic use of a 124I radiopharmaceutical, simultaneously, as an imaging and therapeutic agent. TRIAL REGISTRATION: NCT01502917; https://clinicaltrials.gov/study/NCT01502917.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Souweidane MM, Bander ED, Zanzonico P, et al. Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma. Neuro Oncol. 2025. PMID: 39969230. doi:10.1093/neuonc/noaf039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。